MG-001 phase 1b/2a
73 evidence topics · 7 sources
Objective
Primary objective of safety and tolerability; secondary objectives of disease severity and biomarkers
Protocol objectives: safety, tolerability, and manufacturing feasibility
Objectives of the phase 1b and phase 2a portions: maximum tolerated dose and dosing schedule
Objective of the 12-month follow-up and retreatment report
“We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Here, we report the results of both the final, 12‐month follow‐up analyses and the optional retreatment of participants who met protocol‐specific retreatment criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Eight U.S. sites, recruitment January 2020 to August 2022
Academic centers and community neurology clinics
Study design
Prospective, open-label, multicenter, nonrandomized phase 1b/2a design
Part 1 intrapatient dose escalation and Part 2 dosing schedules
“Part-2 (n=11) tested 3 dosing schedules at the MTD: twice weekly for 3 weeks (Arm-1), weekly for 6 weeks (Arm-2), and monthly for 6 months (Arm-3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enrollment into Part-2 would stop when sufficient data on safety, feasibility, and clinical activity had been gathered to permit the selection of the dosing schedule to be tested in later-stage trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Assignment to Part 2 arms by investigator discretion and participant preference
“Participants in Part-2 were assigned to a treatment Arm at investigator’s discretion, taking into consideration each participant’s preferences (predominantly determined by the time burden of each infusion schedule) and enrolment to date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Assessment schedule and safety monitoring committee
“Participants were evaluated at screening, infusion visits, Weeks 8, 12, 16, and 20, and Months 6, 9, and 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Throughout the study, the clinical data were reviewed periodically by a sponsor-funded safety monitoring committee containing experts who have no other relationship with the sponsor or trial conduct.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term follow-up schedule of the weekly-dosing arm
“The group that received Descartes‐08 as six weekly infusions (Arm‐2) had the longest follow‐up, with evaluations at Months 2, 3, 4, 5, 6, 9, and 12 counting from the first infusion, and was therefore included in this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Key inclusion criteria: age, MGFA class, autoantibody status, and MG-ADL score
“Key inclusion criteria were: age ≥18 years; diagnosis of MG (MGFA Disease Class III–IV in Part-1, Class II–IV in Part-2) with presence of an MG-associated autoantibody (anti-acetylcholine receptor [AChR], muscle specific kinase [MuSK], or low-density lipoprotein receptor-related protein 4 [LRP4]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If seronegative, unequivocal response to cholinesterase inhibitors, and abnormal repetitive nerve stimulation, or increased jitter on single-fiber EMG was required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had to have MG Activities of Daily Living (MG-ADL) score ≥6 at both screening and baseline; and requiring immunosuppression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key exclusion criteria
“Key exclusion criteria were the presence of a major chronic illness that was not well managed; IVIg or plasma exchange within 4 weeks of baseline (first infusion) visit; and the use of non-permitted immune modulators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stable background immunosuppression required before enrollment
Protocol exclusions for B-cell depleting agents, calcineurin inhibitors, FcRn antagonists, and complement inhibitors
Protocol exclusions for hepatitis, HIV, tuberculosis, and active infection
Treatment
Autologous CD8+ T-cell product transfected with RNA, prepared from leukapheresis without withholding immunosuppression
“Descartes-08 is an autologous CD8+ T-cell-only product that is transfected with RNA to express anti-BCMA targeting CAR protein over the course of a week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible participants underwent leukapheresis to obtain peripheral blood mononuclear cells (PBMCs), from which Descartes-08 was prepared following Good Manufacturing Practices.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Immunosuppression was not withheld before the collection of PBMCs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aliquot(s) of cells were thawed at each infusion visit and infused by a peripheral intravenous line.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part 1 dose levels and Part 2 dose of 52.5 × 10⁶ CAR+ cells per kilogram
“In Part-1 of the study (n=3), each participant received three ascending weekly doses of Descartes-08 as a 15–30-minute intravenous infusion of 3·5 × 10⁶ CAR+ cells/kg (Dose Level 1, DL1) 17·5 × 10⁶ CAR+ cells/kg (DL2), and 52·5 × 10⁶ CAR+ cells/kg (DL3) to determine the maximum tolerated dose (MTD) at the safety interim analysis, prior to proceeding to Part-2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The allowed dose margin was ±45% for all dose levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Part‐2, up to 10 participants per arm with MGFA Class II–IV AChR‐Ab+, MuSK‐Ab+, or seronegative MG received the maximum administered dose of Descartes‐08 from Part‐1—which was 52.5 × 10⁶ viable CAR+ cells per kilogram—twice‐weekly for 3 weeks (Arm‐1), once‐weekly for 6 weeks (Arm‐2) or once‐monthly for 6 months (Arm‐3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting, post-infusion monitoring, premedication, and no lymphodepletion
“Lymphodepletion chemotherapy was not used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For Part-1, participants were admitted to the hospital for their first infusion and observed as inpatient for three days and thereafter as outpatient daily until Day 7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who received Descartes-08 as outpatients were observed for an hour post-infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Any participant with a fever of ≥38°C (≥100·4°F) within 7 days of infusion was admitted for 24-hour observation and evaluated for an infectious etiology with blood and urine cultures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Descartes‐08 was administered in an outpatient setting with 2 h of post‐infusion monitoring and without lymphodepletion chemotherapy (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both parts, the participants received acetaminophen and diphenhydramine as premedication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Permitted and prohibited concomitant medications
“Permitted MG concomitant medications were corticosteroids (≤40 mg prednisone/day equivalent), azathioprine, mycophenolate mofetil, pyridostigmine and complement inhibitors, provided the dose was stable for at least 8 weeks before the first infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No dosing change was allowed for concomitant MG-specific medications during the study, other than corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The dose of corticosteroids was not allowed to be increased but it could be tapered at the site investigator’s discretion after Week 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) were prohibited within 4 weeks of baseline and during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other biologics, including rituximab and efgartigimod, were prohibited within 8 weeks of baseline and during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturing from all participants and cell doses delivered
“We successfully produced Descartes-08 from all patients despite their use of immunosuppressants, with a potency comparable to a healthy volunteer (Figure s1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three Part-1 participants received a median of 6·4 × 10⁹ CAR+ cells (range 6·3–7·2) over three infusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Part-2, 11 participants received a median of 17·3 × 10⁹ CAR+ cells (range 9·65–33·12) divided across a median of six infusions (range 3–6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Primary endpoints: tolerability in Part 1 and adverse events in Part 2
“The primary objective of Part-1 was to determine tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint of Part-2 was safety (frequency and severity of AEs) to final follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale: toxicities of DNA CAR T-cells and the premise of RNA engineering
“These aspects of DNA CAR T-cells limit their suitability for use beyond advanced cancers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To expand the range of conditions treatable with CAR T-cells beyond cancer, we engineered these cells with RNA (rCAR-T), rather than DNA, on the premise that the temporary, non-replicable influence of mRNA would confer predictable PK and consequently a more favorable safety profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoints: MG-ADL, QMG, MGC, MG-QoL-15r, and MG PIS without a prespecified efficacy time point
“Secondary endpoints were mean changes from baseline at each follow-up visit for up to 12 months (a primary efficacy time point was not pre-specified) in four validated scales of MG severity: Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative MG (QMG), MG Composite (MGC), and MG Quality of Life 15-revised (MG-QoL-15r) scores, as well as the MG Post-Intervention Status (MG PIS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Protocol responder endpoints: 2-point MG-ADL and QMG changes and 3-point MGC change
Outcome scales and clinically meaningful change thresholds
“MG-ADL is an 8-item, 24-point, patient-reported scale that assesses the impact of myasthenic symptoms on daily functioning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By convention, a 2-point change is considered clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“QMG is a standardized, quantitative, 39-point scoring system consisting of 13 provider-assessed items, which include hand grip strength and forced vital capacity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MGC is a 10-item, 60-point weighted instrument composed of selected components of the MG-ADL and QMG scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 3-point change in QMG and MGC is considered clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, there is no consensus as to what is considered a clinically meaningful change in MG-QoL-15r.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment: up to 18 participants
Enrolled participants: 3 in Part 1 and 11 in Part 2
Weekly-dosing arm analyzed through 12 months: 7 participants
Description of analysis sets
Safety analysis set: all 14 participants who received at least one dose
Week 12 efficacy set: Part 2 Arm 1 and Arm 2 participants who completed 12-week follow-up
“Includes data from Part-2 (Arm-1 and Arm-2) participants who completed 12-week follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One Arm 1 participant was off-study prior to the first post-treatment assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive statistical methods
“Baseline demographics and primary endpoints (type and frequency of AEs) were analyzed using descriptive statistics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary and exploratory endpoints were expressed as mean change with a 95% Confidence Interval (CI), or proportion with Standard Error (SE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Screening, eligibility failures, and withdrawals
“Sixteen patients were screened. Two did not qualify due to low baseline MG-ADL score (n=1) or lack of generalized disease (n=1) (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two of the 11 participants (18%) in Part-2 withdrew and did not complete all planned infusions: one due to urticaria (Arm 1, see below) and another for personal reasons unrelated to safety (Arm 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The single Arm-3 participant withdrew from study after receiving 3 of 6 planned monthly infusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up duration and Arm 1 discontinuations by Week 16
“Median follow-up in Part-2 was 5 months (range: 3–9 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By Week 16, all Arm-1 participants were off-study due to AE (n=1) or worsening symptoms requiring additional treatment (n=2); all 7 Arm-2 participants continue having MG scale scores below baseline during 6 months median follow-up (range 4–9 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Arm 1 and Arm 3 discontinuation before full follow-up
Baseline characteristics
Demographics and baseline characteristics by part and arm: all 14 participants
Disease severity at screening, antibody status, and concomitant therapy: all 14 participants
“Most participants (10 of 14, 71%) had MGFA class III disease, with a median MG-ADL score of 11 (range 6–15), median QMG score of 16 (range 8–24), and median MGC score of 23 (range 12–30) at screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eleven patients had a history of anti-AChR antibodies; two had anti-MuSK antibodies; and one was seronegative for AChR, MuSK and LRP4 antibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most participants (11 of 14, 79%) continued pyridostigmine, and 10 of 14 (71%) received corticosteroids throughout the study (mean dose 19.5 mg/day, range 5–40 mg/day).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants had previously received at least one of the following: IVIg, corticosteroids, non-steroidal immune suppressants, or PLEX (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm characteristics: 7 participants
“Seven patients were enrolled in Arm‐2, of whom 5 were females, 4 (57%) were AChR‐Ab+, 3 (43%) had previously undergone thymectomy, and all had received previous immunosuppressive treatments and IVIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most participants continued the use of pyridostigmine and corticosteroids throughout the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Part 1: variable reductions in severity scores and one prednisone taper
“Part-1 participants showed variable reductions in mean MG-ADL, QMG, MGC, and QoL-15r scores at Weeks 3–24 (Figure s2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant tapered their dose of prednisone from 40 mg daily before treatment to 25 mg daily at final (12-month) follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part 2 Arms 1 and 2: mean changes at Week 12 and onset of response
“Part-2 participants enrolled in Arms 1 and 2 experienced decreases in all disease severity scores by Week 5; in Arm-2, these reductions deepened further by Week 8 and subsequently plateaued (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean [95% CI] improvements at Week 12 — the last time point when data for all Arm-1 and Arm-2 participants were available — were −5·9 [−9, −2·8] (MG-ADL), −7 [−11, −3] (QMG), −14 [−19, −9] (MGC), and −9 [−15, −3] (MG-QoL-15r) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Repeatable numerical improvement in multiple MG scales pointing towards clinical symptom improvement was observed in all 9 participants who reached Week 8, and 8 of 9 (89%) at Week 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Measures of disease severity at Week 12 by arm and antibody type: Part 2 participants with 12-week follow-up
Responder definitions: prespecified 2-point and reported 3-point QMG thresholds, and post hoc MG-ADL depth of response
“All participants who had the pre-specified ≥2-point improvement in QMG also had a ≥3-point improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post-hoc analysis of depth of response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal symptom expression, IVIg independence, and concomitant medications: Part 2 Arm 2
“Three Arm-2 participants (43%) achieved minimal symptom expression (MSE, defined as MG-ADL of 0 or 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in at least one post-treatment follow-up; two of the three have maintained MSE through the most recent (6-month) follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two other Arm-2 participants who, before enrollment, required weekly or biweekly IVIg infusions have not needed further IVIg during follow-ups at 4 and 6 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no changes in concomitant MG-specific medications reported in any Part-2 participants during the study period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm at Month 3: clinically meaningful improvement in all 7 participants
“All seven participants who received six weekly infusions of Descartes‐08 exhibited clinically meaningful improvement in common MG severity scales (MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15‐revised) at Month 3 without significant toxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm at Month 9: mean changes in MG-ADL, MGC, QMG, and QoL-15r, 7 participants
“At Month 9, approximately 7 months after the last infusion and without new or increased MG‐directed drugs, all participants continued to experience substantial clinical responses as measured by MG‐ADL (mean change −6.3 [95% CI −3.5 to −9.1], Figure 2A), MGC (−16.6 [−13.4 to −19.5], Figure 2B), QMG (−8.4 [−5.2 to −11.6], Figure 2C), and QoL‐15r (−12 [−8 to −16], Figure 2D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm at Month 12: maintained response in 5 of 7 participants
“At Month 12, 5 of the 7 participants maintained clinically meaningful improvement, including one with MSE, with mean change in MG‐ADL −4.6 [95% CI −8.8 to −0.4], MGC −11.3 [−18.0 to −4.6], QMG −6.3 [−10.5 to −2.0] and QoL‐15r −7.7 [−15.6 to −8.4].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this 12‐month follow‐up, we observed durable responses sustained up to 12 months in 5 of the 7 (71%) participants who received six once‐weekly doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm: prednisone dose and IVIg use through Month 12
“Five of the 7 participants received prednisone at baseline, with a median daily dose of 17.5 mg. By Month 12, the median dose decreased to 5 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neither of the two participants who were receiving IVIG once and twice monthly at baseline required IVIG during the 12 months of follow‐up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm: anti-AChR antibody reductions through Month 12
“Three of the four participants with reported anti‐AChR antibody exhibited detectable levels at baseline, and all three showed reductions in antibody levels by Month 6 (−17%, −44%, and −65%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These reductions continued at Month 9 (−35%, −100% [undetectable], and −70%), and persisted at Month 12 (−33%, −44% and −65% reductions, Figure 5A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relapse at Month 12 and Month 18 and retreatment in the weekly-dosing arm
“Two participants with anti‐AChR antibody‐positive MG experienced worsening disease at Month 12 and became eligible for retreatment (Table S1); both opted for retreatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Month 18 after initial treatment, a third participant, with triple‐seronegative MG, experienced MG worsening and opted for retreatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Retreatment consisted of repeat apheresis followed by six once‐weekly infusions of target 52.5 × 10⁶ viable CAR+ cells per kg in an outpatient setting and without lymphodepletion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All three participants experienced a rapid improvement in MG‐specific clinical scores; two achieved MSE by Week 8, which was maintained through 12 months of post retreatment follow‐up (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The third participant experienced similar improvement in MG severity scores to their initial treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company-reported retreatment analysis: third phase 2a retreated participant at Month 12
Company-reported retreatment analysis: pooled phase 2a and 2b case series design, September 2026
Company-reported retreatment analysis: baseline characteristics of the pooled case series, 5 participants
| Characteristic | Participants (n=5) |
|---|---|
| Age, mean (SD) | “58 (12) years” |
| Age range | “49–79” |
| Women, n (%) | “4 (80%)” |
| AChR+ gMG, n (%) | “4 (80%)” |
| MG-ADL at baseline before initial treatment, mean (SD) | “9.2 (3.1)” |
| MG-ADL at baseline before retreatment, mean (SD) | “9.6 (3.4)” |
| Median interval between end of initial treatment course and first retreatment infusion | “16.6 months”; “(range 11.7–22.6)” |
Company-reported retreatment analysis: MG-ADL and MGC changes at Month 12 after retreatment, 5 participants
Health-related quality of life and patient-reported outcomes
MG-QoL-15r change at Week 12 by arm and antibody type: Part 2 participants with 12-week follow-up
| Measure at Week 12 | All, n=9 (mean change, 95% CI) | Arm 1, n=2 (individual values) | Arm 2, n=7 (mean change, 95% CI) | AChR+, n=6 (mean change, 95% CI) | MuSK+, n=2 (individual values) | Seronegative, n=1 |
|---|---|---|---|---|---|---|
| MG-QoL-15r | “−9 [−15, −3]”View highlighted excerpt for this quote | “−8, +4”View highlighted excerpt for this quote | “−11 [−23, +1]”View highlighted excerpt for this quote | “−8 [−17, +1]”View highlighted excerpt for this quote | “−10, −6”View highlighted excerpt for this quote | “−14”View highlighted excerpt for this quote |
Safety results
No dose-limiting toxicity, cytokine release syndrome, or neurotoxicity
“There was no dose-limiting toxicity, cytokine release syndrome (CRS), or neurotoxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no dose-limiting toxicities (DLTs), treatment-related SAEs, or Grade ≥3 AEs in Part-1 (Table 2), making DL3 the MTD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse events: influenza before treatment, grade 3 urticaria, and myocardial infarction
“One SAE unrelated to Descartes-08 (Grade 2 influenza requiring hospitalization, which occurred after apheresis but before treatment initiation) was reported in Part-1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two SAEs were reported in Part-2. The first was Grade 3 urticaria 24 hours after the third infusion in a participant with a prior history of drug-induced urticaria; skin biopsy was consistent with a typical drug reaction, and serum tryptase and cytokine levels were normal (Table s3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The urticaria was deemed possibly related to Descartes-08 and resolved completely after the administration of intravenous steroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second SAE was a non-ST segment elevation myocardial infarction occurring 72 hours after the sixth infusion in an 83-year-old man with a history of hypertension and hyperlipidemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The investigator deemed the event unrelated to Descartes-08.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events related to Descartes-08 by part and arm: all 14 participants
Adverse event counting rules and grade distribution
“Each AE was counted once per patient, at the highest grade reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relatedness includes possibly, probably, or likely” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no Grade ≥3 events reported in Part-1, and no Grade 2 or Grade 4 events reported in Part-2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infusion-associated fever without cytokine release syndrome markers
“Headache, fever, and nausea were the most common treatment-related AEs in Part-2, reported in 5 (45%), 4 (36%), and 4 (36%) of 14 patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All fevers occurred 4–6 hours after infusion and resolved within 24 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of these patients had positive urine or blood cultures or received empiric antibiotics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no episodes of hypotension, hypoxia, or requirement for the use of tocilizumab or steroids for treatment of or prevention of CRS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fevers were not associated with elevated markers of CRS (interleukin-6, interleukin-2, and tumor necrosis factor-α).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Humoral immunity: immunoglobulins and vaccine titers through Week 12
“No patient showed evidence of functional immunosuppression (i.e. new hypogammaglobulinemia or disappearance of previously therapeutic levels of vaccine titers) or opportunistic infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anti-tetanus IgG antibodies were detected in all 9 participants (median [range] at Day 1 93·7 [8·5–850·9] Units/mL) and did not change (Figure 3G).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median total IgG among the 9 participants was 1325 [range 383–2862] mg/dL and decreased up to 18% [95%CI −6–42%] by Week 12, while IgA and IgM levels remained unchanged during treatment (Figures 3H–I).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm through Month 12: no new product-related adverse events
Weekly-dosing arm through Month 12: meningococcal antibody titers and total immunoglobulin
“Five of the seven participants had circulating anti‐meningococcal antibodies at baseline, all from prior vaccination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a small but detectable decrease in these antibodies at Month 3, which deepened by Month 9 (−48% [−25% to −75%]) and stabilized by Month 12 to lower but still protective levels (−48% [−35% to −69%], Figure 5B), following a similar pattern to the anti‐AChR antibody reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, there was no appreciable decrease in total immunoglobulin (Figure 5C), other vaccine‐associated antibodies (Figure S1), or soluble BCMA (sBCMA, Figure 6A), indicating that the targeting of BCMA‐positive plasma cells was not indiscriminate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cumulative open-label safety: anaphylaxis, CRS, ICANS, and hematologic toxicity across 14 participants and 88 infusions
“In contrast, there were no cases of anaphylaxis reported across 14 patients treated and 88 administered infusions with Descartes‐08 in MG, including in 3 participants who received a total of 12 infusions each.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No cases of CRS or ICANS were observed among the 14 open‐label MG‐001 participants dosed with Descartes‐08, and no reported use of tocilizumab or corticosteroid.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As there is no lymphodepletion chemotherapy required, there were no associated hematologic toxicities in any of the 14 patients with MG who received Descartes‐08.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety after retreatment in the weekly-dosing arm, 3 participants
“The safety profile was unchanged compared to the initial treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, the three participants reported fewer adverse events after retreatment while experiencing the same or better numeric improvement across MG severity scales all the way to MSE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company-reported retreatment analysis: safety events after initial treatment and retreatment, 5 participants
| Safety event | Initial treatment (n=5) | Retreatment (n=5) |
|---|---|---|
| Serious adverse events | “1” | “0” |
| Infusion-related reaction | “16/30 infusions” | “17/30 infusions” |
| Infusion-related reaction, grade 1 | “10” | “12” |
| Infusion-related reaction, grade 2 | “6” | “5” |
| Tachycardia | “1” | “5” |
| CRS | “0” | “0” |
| ICANS | “0” | “0” |
| Cytopenias | “0” | “0” |
| Hypogammaglobulinemia | “0” | “0” |
Company-reported retreatment analysis: tolerability through Month 12 after retreatment
Study limitations
Summary
- Design: the study was open label, nonrandomized, and without a control arm, and the authors state that a placebo effect cannot be excluded and that comparison with historical controls is not conclusive. Part 2 participants were assigned to dosing arms at the investigator's discretion, taking participant preference into account.
- Sample size: 14 participants were enrolled (3 in Part 1 and 11 in Part 2), and no formal power analysis was performed. The week 12 efficacy analysis included 9 Part 2 participants, and only 2 participants had MuSK antibody-positive disease and 1 had seronegative disease. Three participants had MGFA class II disease, which the authors note may improve to minimum symptom expression with conventional treatment.
- Endpoints: efficacy measures were secondary endpoints with no prespecified primary efficacy time point, and the analysis of MG-ADL decreases of 6 points or more was post hoc. Corticosteroid tapering was permitted after week 4 at the investigator's discretion, and the authors state that an effect of the unchanged maintenance dose cannot be excluded in the absence of a control arm.
- Follow-up and attrition: median follow-up in Part 2 was 5 months (range 3 to 9) in the initial report. By week 16 all twice-weekly arm participants were off study (adverse event, n = 1; worsening symptoms, n = 2), and the single monthly-arm participant withdrew after 3 of 6 infusions. The 12-month analysis is limited to the 7 weekly-arm participants, of whom 5 maintained clinically meaningful improvement at month 12.
- Retreatment and biomarkers: the authors state that more experience with initial treatment and retreatment is needed, that allergic reactions including anaphylaxis cannot be excluded, and that circulating antibody titers may not reflect tissue concentrations. The pooled retreatment case series of 5 participants is company-reported.
- Reporting: the sponsor took part in the design, data collection, interpretation, analysis, manuscript writing, and decision to submit. The text gives the most common treatment-related adverse events in Part 2 as 5 (45%), 4 (36%), and 4 (36%) “of 14 patients”, while the table reports these counts for Part 2 (n = 11). The month-12 MG-QoL-15r change is printed as “−7.7 [−15.6 to −8.4]”, an interval that does not contain its point estimate.
Small, open-label, uncontrolled design: author-stated limitations
“Our study has the inherent limitations of a small, open-label trial, including the potential for placebo effect, and limited ability to draw inferences from secondary, exploratory and subgroup analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, three participants had MGFA Class II MG, which may improve to MSE even with conventional treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although it is unlikely that the observed magnitude of symptom improvement could be attributed solely to this unchanged maintenance dose, or to the placebo effect, in the absence of a control arm such a possibility cannot be excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, there were only 2 participants with MuSK, and only 1 with seronegative MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparison to historical controls is not conclusive, and therefore a more complete assessment of efficacy is underway in a randomized, placebo-controlled study using six weekly doses of Descartes-08 for MG (NCT04146051).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor role in design, analysis, and reporting
Limited retreatment experience, allergic reactions, and antibody titers as biomarkers
“More experience with initial treatment and retreatment would be needed to confirm this hypothesis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As with any form of biologic therapy, allergic reactions, including anaphylaxis, cannot be excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the onset of clinical improvement was more rapid than the autoantibody reduction, and circulating antibody titers may not accurately reflect their concentration at the tissue level.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote